Endotoxin Activity Assay and Microcirculation in Severe Sepsis

NCT ID: NCT02452138

Last Updated: 2015-12-18

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

100 participants

Study Classification

OBSERVATIONAL

Study Start Date

2016-01-31

Study Completion Date

2017-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Endotoxin is the major mediator of sepsis resulted from systemic inflammatory response syndrome induced by gram-negative bacteria infection. The endotoxin related inflammatory response and hypercoagulation can result in microcirculatory dysfunction. When microcirculatory dysfunction is severe, it can induce multiple organ dysfunction syndrome and death. This is a prospective observational study, and it will not influence the sepsis treatment decision of the medical care team. The critically ill severe sepsis patients will be enrolled only if they meet all inclusion criteria, do not meet any exclusion criteria and sign the consent form after explanation of the aim and process of the trial by the primary investigator or research personnel. After enrollment, the patient will receive serum assay of endotoxin activity (EAA) and endocan level. The patient will also receive examination of sublingual microcirculation by using the incident dark field video microscope. After 24 hours, the patient will receive assay of endocan level and examination of sublingual microcirculation. This study will record the vital signs, laboratory data, dose of vasopressors and inotropic agents, and severity of organ dysfunction. After 28 days, this study will check the survival, stay of intensive care, stay of hospital, ventilator day, and the results of culture of pathogens. The patients will be assign to the following three groups by the EAA level: low EAA group (\< 0.40 EAA units); intermediate EAA group (0.40-0.59 EAA units); and high EAA group (≧ 0.60 EAA units). This grouping will be used for statistical analysis and comparison. The primary goal of this study is to investigate the difference of the prevalence of gram-negative bacteria infection, pathogen, infection source, microcirculation, the severity of disease, and the prognosis among these three groups.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Sepsis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Low EAA

Endotoxin Activity Assay \[EAA\] level \< 0.40 EAA units

Severe sepsis management

Intervention Type OTHER

Intermediate EAA

Endotoxin Activity Assay \[EAA\] level between 0.40-0.59 EAA units

Severe sepsis management

Intervention Type OTHER

High EAA

Endotoxin Activity Assay \[EAA\] level \>= 0.60 EAA units

Severe sepsis management

Intervention Type OTHER

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Severe sepsis management

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* patients with the following infections: intraabdominal infection, pneumonia, urinary tract infection, blood stream infection, or wound infection
* patients must also meet any one of the following criteria for severe sepsis

* SBP \< 90 mm Hg, MAP \< 65 mm Hg, or requirement of vasopressors or inotropics
* PaO2/FiO2 \< 300
* Creatinine level \> 2 mg/dL or increase \> 0.5 mg/dL; or urine output \< 0.5 mL/kg/h more than 2 hours
* Bilirubin level \> 4 mg/dL
* Platelet count \< 100 k/uL or decrease more than 50%
* INR \> 1.5 or aPTT \> 60 sec
* GCS \< 13 or 9T
* Lactate \> 2 mmol/L (with pH \< 7.3 or base excess \< -5 mmol/L)

Exclusion Criteria

* younger than 20 yeras old or greater than 99 years old
* the onset of severe sepsis before enrollment is greater than 24 hours
* pregnant
* have received plymyxin-B hemoperfusion within 24 hours before enrollment
* non-native speaker
Minimum Eligible Age

20 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

National Taiwan University Hospital

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Yu-Chang Yeh, MD, PhD

Role: PRINCIPAL_INVESTIGATOR

National Taiwan University Hospital

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Yu-Chang Yeh, MD, PhD

Role: CONTACT

Phone: 886-9-10513711

Email: [email protected]

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

201503015RINB

Identifier Type: -

Identifier Source: org_study_id